<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Certain malignant B cells rely on B-cell receptor (BCR)-mediated survival signals </plain></SENT>
<SENT sid="1" pm="."><plain>Spleen tyrosine kinase (Syk) initiates and amplifies the BCR signal </plain></SENT>
<SENT sid="2" pm="."><plain>In in vivo analyses of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, Syk inhibition induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>These data prompted a phase 1/2 clinical trial of fostamatinib disodium, the first clinically available oral Syk inhibitor, in patients with recurrent B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) </plain></SENT>
<SENT sid="4" pm="."><plain>Dose-limiting toxicity in the phase 1 portion was <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and 200 mg twice daily was chosen for phase 2 testing </plain></SENT>
<SENT sid="5" pm="."><plain>Sixty-eight patients with recurrent B-NHL were then enrolled in 3 cohorts: (1) diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), (2) follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), and (3) other NHL, including mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>), mucosa-associated lymphoid tissue <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and small lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL) </plain></SENT>
<SENT sid="6" pm="."><plain>Common toxicities included <z:hpo ids='HP_0002014'>diarrhea</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp>, cytopenias, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and <z:hpo ids='HP_0002018'>nausea</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Objective response rates were 22% (5 of 23) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, 10% (2 of 21) for FL, 55% (6 of 11) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL, and 11% (1/9) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Median progression-free survival was 4.2 months </plain></SENT>
<SENT sid="9" pm="."><plain>Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>/CLL </plain></SENT>
<SENT sid="10" pm="."><plain>This trial was registered at www.clinicaltrials.gov as #NCT00446095 </plain></SENT>
</text></document>